The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Early change in tumor size from waterfall plot analysis and RECIST response as predictor of overall survival (OS) in advanced, chemotherapy-refractory colorectal cancer (ACRC): NCIC CTG/AGITG CO.17 study.
G. A. Van Hazel
Consultant or Advisory Role - Amgen; Merck Serono
D. Tu
No relevant relationships to disclose
N. C. Tebbutt
Consultant or Advisory Role - Merck Serono
Research Funding - Merck Serono
D. J. Jonker
Consultant or Advisory Role - Amgen (U); Bristol-Myers Squibb (U)
Honoraria - Amgen; Bristol-Myers Squibb
T. J. Price
Consultant or Advisory Role - Merck Serono (U)
C. O'Callaghan
No relevant relationships to disclose
J. R. Zalcberg
Research Funding - Amgen; Merck Serono
Other Remuneration - Amgen; Merck Serono
M. Taylor
No relevant relationships to disclose
A. H. Strickland
No relevant relationships to disclose
A. T. Tomiak
No relevant relationships to disclose
D. Yip
No relevant relationships to disclose
J. Simes
Research Funding - Bristol-Myers Squibb; Merck Serono
S. K. Yadav
No relevant relationships to disclose
M. Links
No relevant relationships to disclose
M. J. Burnell
No relevant relationships to disclose
M. Jefford
No relevant relationships to disclose
C. S. Karapetis
Consultant or Advisory Role - Merck Serono